ITBMed's Unattributed Round

ITBMed raised a round of funding on April 05, 2018. Investors include Pablo Legorreta.

ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics primarily for organ transplantation and stem cell transplantation. The lead candidate drug Siplizumab is a monoclon…

Articles about ITBMed's Unattributed Round: